Revenue Opportunities and Growth Strategies - Sharecare's revenue opportunities from existing clients in high-cost areas represent a potential $1 billion revenue opportunity[91] - Sharecare aims to expand its existing client relationships by increasing engagement and enrollment through targeted marketing efforts[91] - The company is focused on cross-selling provider solutions to approximately 6,000 health system clients[92] - The company is actively investing in sales and marketing to acquire new clients across various sectors[91] - The company continues to explore acquisitions to drive growth and value, leveraging its expanding member base and client channels[95] Product Development and Innovation - The company launched Sharecare+, a digital-first advocacy solution, in January 2023 to enhance benefits navigation and clinical engagement[93] - Sharecare's platform is designed to integrate fragmented healthcare solutions into a comprehensive virtual care platform[79] - The company is committed to evolving its products to meet the changing demands of the digital healthcare industry, accelerated by the COVID-19 pandemic[94] - Sharecare's enterprise solutions cater to a diverse client base, including large employers and government organizations[81] Financial Performance and Revenue Trends - Revenue decreased by $16.1 million, or 15%, from $110.4 million in Q2 2023 to $94.3 million in Q2 2024, primarily due to declines in the enterprise channel[109] - Revenue decreased by $41.5 million, or 18%, from $226.6 million in 2023 to $185.1 million in 2024[119] - The enterprise channel revenue decreased by $17.9 million, or 28%, from $64.1 million in Q2 2023 to $46.2 million in Q2 2024, attributed to customer terminations and the shutdown of unprofitable operations[110] - The enterprise channel revenue decreased by $41.1 million, or 31%, from $134.2 million in 2023 to $93.1 million in 2024[120] - The provider channel revenue increased by $0.9 million, or 2%, from $58.2 million in 2023 to $59.1 million in 2024[120] Expenses and Cost Management - Costs of revenue decreased by $11.8 million, or 19%, from $62.9 million in Q2 2023 to $51.2 million in Q2 2024, due to revenue decreases and optimization efforts[111] - Sales and marketing expenses decreased by $1.4 million, or 9%, from $15.0 million in Q2 2023 to $13.6 million in Q2 2024, driven by reduced headcount and sponsorship costs[112] - Product and technology expenses decreased by $2.3 million, or 14%, from $17.0 million in Q2 2023 to $14.7 million in Q2 2024, due to lower labor costs and amortization of a non-cash asset[113] - General and administrative expenses increased by $4.3 million, or 12%, from $35.4 million in Q2 2023 to $39.7 million in Q2 2024, influenced by increased share-based compensation and legal costs related to a pending merger[114] - Depreciation and amortization increased by $2.1 million, or 15%, from $14.2 million in Q2 2023 to $16.3 million in Q2 2024, primarily due to new software being placed into service[115] Merger and Acquisition Activities - The pending merger with Altaris is expected to complete in the second half of 2024, subject to stockholder approval and other closing conditions[88] - The completion of the merger is subject to customary closing conditions, including stockholder approval and regulatory clearances[86] - The company has agreed to a termination fee of $17.7 million under specified limited circumstances as part of the Merger Agreement[147] - The company may be obligated to pay a termination fee of $17.7 million under certain circumstances related to the Merger Agreement[154] - The company incurred $4.730 million in acquisition-related costs for the three months ended June 30, 2024, compared to $267,000 for the same period in 2023, showing a substantial rise in costs associated with acquisitions[140] Cash Flow and Financial Position - The company had $85.2 million in cash and cash equivalents as of June 30, 2024, with $52.4 million available for borrowing under the Revolving Facility[146] - The company believes its cash on hand will be sufficient to meet its operating cash flow and working capital needs in the short term[148] - Net cash used in operating activities for the six months ended June 30, 2024 was $23.6 million, an increase of $2.4 million from $21.2 million in the same period of 2023[150] - Net cash used in investing activities for the six months ended June 30, 2024 was $15.7 million, compared to $15.2 million for the same period in 2023[151] - Net cash used in financing activities for the six months ended June 30, 2024 was $3.6 million, primarily due to share repurchases of $3.7 million[153] Market Risks and Future Outlook - The company has been exposed to market risks such as interest rate, foreign currency exchange, and financial instrument risks, although currently these risks are not material to its financial condition or results of operations[175] - Future exposure to market risks may increase as the business continues to evolve[175] - The company expects capital expenditures and working capital requirements to continue to increase in the immediate future as it seeks to expand its solution offerings[148] Adjusted Financial Metrics - Adjusted EBITDA is used by management to assess operating performance, excluding various non-recurring costs[127] - Adjusted EBITDA for the three months ended June 30, 2024, was $7,000, while for the same period in 2023, it was $3,288, indicating a significant improvement[140] - Adjusted net loss for the six months ended June 30, 2024, was $27.438 million, compared to $20.826 million for the same period in 2023, reflecting an increase of approximately 31.5%[140] - The adjusted loss per share for the three months ended June 30, 2024, was $(0.04), compared to $(0.03) for the same period in 2023, reflecting a slight increase in loss per share[140] Legal and Compliance Matters - The company is pursuing recovery of $50 million in fees from a customer in a contract dispute, which has negatively impacted financial results[97] - Non-operating, non-recurring costs included legal matters and ERP implementation costs, which are not expected to recur in the foreseeable future[128][130]
Sharecare(SHCR) - 2024 Q2 - Quarterly Report